BiotechTube
NovaRock Biotherapeutics

NovaRock Biotherapeutics

Cambridge, United States· Est.
novarockbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $55M

Overview

NovaRock Biotherapeutics is a private, preclinical-to-clinical stage biotech focused on next-generation antibody therapies for oncology and autoimmunity. The company's lead asset, NBL-028, a CLDN6-CD137 bispecific T cell engager, has received FDA IND clearance to enter Phase 1 trials, marking a significant milestone. NovaRock's proprietary NovaTE platform is designed to create conditionally active T cell engagers with improved safety profiles for solid tumors, positioning the company in a competitive but high-potential therapeutic space.

OncologyAutoimmune Diseases

Technology Platform

NovaTE, a next-generation T cell engager platform designed for conditional activation in the tumor microenvironment to treat solid tumors with improved safety.

Funding History

2
Total raised:$55M
Series A$40M
Seed$15M

Opportunities

The lead program NBL-028 targets CLDN6, a highly tumor-specific antigen expressed in multiple solid tumors with high unmet need, offering a potential best-in-class profile.
The proprietary NovaTE platform could generate a pipeline of safer, more effective T cell engagers for solid tumors, a vast and challenging market segment.
Successful clinical proof-of-concept may attract strategic partnerships or acquisition interest from larger pharmaceutical companies.

Risk Factors

High clinical risk as NBL-028 is a novel, first-in-class bispecific with unproven safety and efficacy in humans.
Intense competition in the T cell engager and targeted oncology space from companies with greater resources.
Significant financial risk as a pre-revenue private company requiring continual capital infusion to fund expensive clinical trials.

Competitive Landscape

NovaRock competes in the crowded and rapidly evolving bispecific T cell engager landscape, dominated by large players like Amgen, Roche, and Regeneron. It faces specific competition from other companies targeting CLDN6, such as BioNTech (with CAR-T and mRNA vaccine candidates). Its differentiation hinges on the conditional activation and safety profile promised by its NovaTE platform.

More companies in Biologics / Biosimilars →More companies in United States →